Invesco
SCR

Invesco’s SIMCERE PHARMACEUTICAL GROUP, ADS SCR Stock Holding History

Invesco’s Portfolio SCR Stock Details SCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-56,272
Closed -$533K – 4383
2013
Q2 		$533K Buy
+56,272
New +$521K ﹤0.01% 3246

Other funds holding SCR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
HK
Horizon Kinetics New York $3.06B AUM 5.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Invesco's SCR Position: Q3 2013 in Review

Invesco sold out of SIMCERE PHARMACEUTICAL GROUP, ADS (SCR) in Q3 2013, closing a stake of 56,272 shares — an estimated $533K sold.

Invesco first reported a position in SCR in Q2 2013 and held it in 1 quarter. The position peaked at $533K in Q2 2013. 20 funds tracked by Wall St. Rank hold SCR as of Q3 2013.

  • Invesco reported no remaining SIMCERE PHARMACEUTICAL GROUP, ADS position as of Q3 2013 after selling out during the quarter.
  • Invesco sold 56,272 SIMCERE PHARMACEUTICAL GROUP, ADS shares in Q3 2013, an estimated $533K.
  • Invesco first reported a position in SIMCERE PHARMACEUTICAL GROUP, ADS in Q2 2013 and held it in 1 quarter.
  • Invesco's SIMCERE PHARMACEUTICAL GROUP, ADS position peaked at $533K in Q2 2013.
  • 20 funds tracked by Wall St. Rank held SIMCERE PHARMACEUTICAL GROUP, ADS as of Q3 2013.

Based on Invesco's 13F filing for Q3 2013, filed 13 Nov 2013.